Short answer
Ceribell, Inc. (CBLL) filed an 8-K current report with the SEC on August 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Fiscal quarter ended June 30, 2026 results announced August 10, 2026.
Ceribell, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended June 30, 2026 results announced August 10, 2026
- Detailed financial results and management commentary provided in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $28.1M, up 33%; product revenue $21.2M and subscription revenue $6.9M signal broad adoption
- Gross margin reached 92% versus 88%, supported by Vietnam manufacturing and one-time tariff refunds
- Net loss widened to $19.3M, or $0.51 per share, as operating expenses increased 37% to $45.9M
- Cash, equivalents, and securities totaled $129.3M; new credit facility adds up to $60M committed capital
- 2026 revenue guidance raised to $114M-$117M, while FDA clearances and October 1, 2026 NTAP eligibility support product expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Ceribell, Inc. 8-K filings
Get the next CBLL 8-K as it lands
Follow CBLL for push alerts, or ask the research agent what this filing means.